Page last updated: 2024-10-25

cilostazol and Peripheral Nerve Diseases

cilostazol has been researched along with Peripheral Nerve Diseases in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Co-treatment with cilostazol prevented paclitaxel-induced dedifferentiation of Schwann cell cultures and demyelination in a mixed culture of Schwann cells and dorsal root ganglia neurons."1.62Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation. ( Imai, S; Iwamitsu, Y; Koyanagi, M; Matsubara, K; Matsumoto, M; Moriya, A; Nakagawa, S; Nakagawa, T; Nakazato, Y; Ogihara, T; Saigo, M; Yonezawa, A, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Haroun, EA1
Mansour, NO1
Eltantawy, A1
Shams, MEE1
Koyanagi, M1
Imai, S1
Iwamitsu, Y1
Matsumoto, M1
Saigo, M1
Moriya, A1
Ogihara, T1
Nakazato, Y1
Yonezawa, A1
Nakagawa, S1
Nakagawa, T1
Matsubara, K1

Trials

1 trial available for cilostazol and Peripheral Nerve Diseases

ArticleYear
Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
    Pharmacotherapy, 2023, Volume: 43, Issue:9

    Topics: Breast Neoplasms; Cilostazol; Female; Humans; Nerve Growth Factor; Paclitaxel; Peripheral Nervous Sy

2023

Other Studies

1 other study available for cilostazol and Peripheral Nerve Diseases

ArticleYear
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
    Neuropharmacology, 2021, 05-01, Volume: 188

    Topics: Animals; Blood Proteins; Breast Neoplasms; Cell Dedifferentiation; Cell Line, Tumor; Cilostazol; Dem

2021